Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon?

  • Kress H
N/ACitations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Comments on an article by W. Schröder et al. (see record [rid]2010-17655-007[/rid]). The authors describe the differential contribution of lopioid and noradrenergic mechanisms to the antinociceptive and antihyperalgesic efficacy of tapentadol in rat models of nociceptive and neuropathic pain. Opioids produce analgesia by binding to opioid receptors in the central nervous system. These receptors are inhibitory, as their activation hyperpolarizes neurons and reduces transmitter release. In view of the unique pharmacology of tapentadol, as outlined by the authors, and in line with the opinion of the above mentioned panel of expert pharmacologists, it seems reasonable to propose that with the new analgesic drug tapentadol a new class of centrally-acting analgesics, designated MOR-NRI, has appeared on stage. (PsycINFO Database Record (c) 2016 APA, all rights reserved)

Cite

CITATION STYLE

APA

Kress, H. G. (2010). Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon? European Journal of Pain, 14(8), 781–783. https://doi.org/10.1016/j.ejpain.2010.06.017

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free